Iovance Biotherapeutics, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. The filing is an annual report, not a standalone fourth-quarter report; quarterly financial results are not clearly provided in the supplied filing text. Amounts below are in U.S. dollars.
Business context
Iovance is a commercial-stage biopharmaceutical company developing individualized tumor-infiltrating lymphocyte (TIL) cell therapies. In May 2023, it acquired worldwide rights to Proleukin (aldesleukin), used in the Amtagvi treatment regimen. After year-end, on February 16, 2024, the FDA approved Amtagvi (lifileucel) under accelerated approval for certain adults with unresectable or metastatic melanoma previously treated with a PD-1 blocker and, when applicable, a BRAF inhibitor.
Financial results and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $1.2 million | $0 |
| Cost of sales | $10.8 million | $0 |
| Research and development | $344.1 million | $294.8 million |
| Selling, general and administrative | $106.9 million | $104.1 million |
| Loss from operations | $460.6 million | $398.9 million |
| Net loss | $444.0 million | $395.9 million |
| Net loss per share, basic and diluted | $1.89 | $2.49 |
| Cash used in operating activities | $361.8 million | $292.8 million |
FY2023 revenue was entirely Proleukin sales, primarily in licensed markets outside the U.S.; no U.S. Proleukin sales were reported. Cost of sales included approximately $9.7 million of amortization of acquired Proleukin developed technology, so the reported excess of cost of sales over revenue is not a measure of underlying product unit economics. Product margins are not meaningfully assessable from the limited sales reported.
At December 31, 2023, the company reported $114.9 million of cash and cash equivalents, $165.0 million of short-term investments and $66.4 million of restricted cash, or $346.3 million combined. Restricted cash includes a $60.0 million letter of credit associated with a future Proleukin acquisition milestone. The cash flow statement reports $181.3 million of cash, cash equivalents and restricted cash at year-end. Financing activities provided $463.0 million, principally from equity sales; investing activities used $155.2 million, including the Proleukin acquisition.
Total liabilities were $195.7 million, including operating lease liabilities of $74.9 million, deferred tax liabilities of $17.3 million and a $1.0 million long-term note payable. The filing reports no off-balance-sheet arrangements. Management stated that available funds, including approximately $197.1 million of estimated net proceeds from a February 2024 stock offering, were expected to fund planned operations and capital expenditures for at least 12 months from issuance of the financial statements.
Material changes versus the prior year
- Revenue began with the Proleukin acquisition: $1.2 million in 2023 versus none in 2022.
- Net loss increased $48.1 million, or 12%, to $444.0 million; operating cash use increased $69.1 million to $361.8 million.
- R&D expense rose 17%, mainly from increased staffing, manufacturing readiness and clinical activity, including Phase 3 TILVANCE-301. SG&A rose 3%.
- Interest income increased to $13.0 million from $3.0 million, reflecting higher rates and a shift toward interest-bearing investments.
- The Proleukin asset acquisition had $222.7 million of total recorded cost, including a $232.7 million developed-technology intangible asset and assumed deferred tax liability. The company issued shares through public and at-the-market offerings, with net proceeds of $463.3 million in 2023.
Outlook, risks and unusual items
- Commercial launch: Management’s priority is launching Amtagvi in the U.S. It set a goal of activating 50 authorized treatment centers within 90 days of the February 24, 2024 PDUFA date. The filing cautions that Amtagvi and Proleukin revenues may not be material during the 12 months following issuance of the financial statements; it provides no specific revenue or profitability guidance.
- Approval conditions and safety: Amtagvi’s approval is accelerated and continued approval may depend on confirming clinical benefit. Its label includes a boxed warning for treatment-related mortality, prolonged severe cytopenia, severe infection, and cardiopulmonary and renal impairment.
- Clinical hold: On December 22, 2023, the FDA placed a partial clinical hold on the registrational IOV-LUN-202 NSCLC trial after a reported fatal serious adverse event potentially related to the lymphodepletion regimen. Enrollment and treatment of new patients were paused; the company said it was working with FDA toward resumption in 2024.
- Development pipeline: TILVANCE-301 is a Phase 3 trial of lifileucel plus pembrolizumab in frontline melanoma, intended to support registration and confirmatory approval. The company planned an endometrial cancer Phase 2 trial in the first half of 2024. Timing, enrollment, safety, efficacy and regulatory outcomes remain uncertain.
- Funding and execution: The company has a $2.0 billion accumulated deficit, expects continuing losses and says additional capital will be needed to execute its broader business plan. Risks include equity dilution, manufacturing scale-up and cost, reliance on contract manufacturers and suppliers, treatment-center activation, reimbursement, competition and the ability to commercialize a complex individualized therapy.
- Contingent payments: The Proleukin acquisition agreement includes an approximately $50 million payment upon first approval of lifileucel in advanced melanoma, plus sales-based deferred consideration and potential earnouts. The filing says the contingent-payment recognition criteria were not met at December 31, 2023; the subsequent Amtagvi approval makes the milestone’s status and cash impact important to verify.
- Other items: Contractual obligations include $116.9 million of facility operating-lease payments and $34.3 million of Proleukin manufacturing and supply purchase obligations. A shareholder derivative matter remained unresolved; the Solomon litigation was dismissed in the company’s favor in October 2023, with an appeal filed in December. Management did not expect pending matters to materially adversely affect financial position, results or cash flows.
Important facts for investors to verify
- Amtagvi launch progress: treatment-center activation, patient referrals, manufacturing throughput, delivery times and realized sales.
- FDA follow-up requirements and progress of the confirmatory TILVANCE-301 trial supporting full approval.
- Whether and when the approximately $50 million Clinigen milestone is payable after FDA approval, and the effect of the $60 million restricted-cash letter of credit.
- FDA actions and the timing and conditions for resuming IOV-LUN-202 enrollment after the fatal-event hold.
- Cash runway and future financing needs, including the impact of ongoing operating cash burn, planned investment and potential share issuance.
- Ability to scale internal and contract manufacturing, meet product quality and release requirements, and supply commercial demand at viable cost.
- Coverage, reimbursement and total treatment costs at authorized centers, including the inpatient-care and associated-regimen economics.
- Clinical and commercial safety outcomes, including risks highlighted in Amtagvi’s boxed warning.